图片来源:摄图网
近日,港股上市公司德琪医药发布公告称,与翰森制药达成独家合作协议,由翰森制药负责塞利尼索在中国大陆的商业化, 德琪医药将获最高2亿元首付款及最高5.35亿元里程碑付款。
据了解,塞利尼索是德琪医药首个上市商业化产品,从Karyopharm引进,...查看全文
$Karyopharm Therapeutics Inc.(KPTI)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2018-01-26 AccNo: 0001144204-18-004055 Size: 89 KB 网页链接
$Karyopharm Therapeutics Inc.(KPTI)$ S-3 - Registration statement under Securities Act of 1933 Filed: 2018-01-26 AccNo: 0001193125-18-021593 Size: 1 MB 网页链接
$Karyopharm Therapeutics Inc.(KPTI)$ 8-K - Current report Filed: 2018-01-25 AccNo: 0001193125-18-019721 Size: 24 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers http...
$Karyopharm Therapeutics Inc.(KPTI)$ 8-K - Current report Filed: 2018-01-25 AccNo: 0001193125-18-019000 Size: 51 KBItem 1.01: Entry into a Material Definitive AgreementItem 9.01: Financial Statements and Exhibits 网页链接
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-01-18,CEO,Kauffman Michael ,卖出,10000普通股, $10.09
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-01-18,CEO,Kauffman Michael ,期权,10000普通股, $0.26
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-01-18,总裁 & CSO,Shacham Sharon ,卖出,10000普通股, $10.09
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-01-18,总裁 & CSO,Shacham Sharon ,期权,10000普通股, $0.26
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-01-08,总裁 & CSO,Shacham Sharon ,卖出,10000普通股, $10.08
$Karyopharm Therapeutics Inc.(KPTI)$ 内部交易: 2018-01-08,总裁 & CSO,Shacham Sharon ,期权,10000普通股, $0.26